Charles Smith to Phosphotransferases (Alcohol Group Acceptor)
This is a "connection" page, showing publications Charles Smith has written about Phosphotransferases (Alcohol Group Acceptor).
Connection Strength
4.011
-
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget. 2016 Sep 13; 7(37):60181-60192.
Score: 0.490
-
Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One. 2012; 7(9):e44543.
Score: 0.371
-
Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res. 2011 Nov; 9(11):1509-19.
Score: 0.346
-
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.
Score: 0.334
-
A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther. 2010 May; 333(2):454-64.
Score: 0.311
-
Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010 Apr; 333(1):129-39.
Score: 0.308
-
Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci. 2008 Apr; 53(4):997-1012.
Score: 0.267
-
Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15; 63(18):5962-9.
Score: 0.199
-
Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA). Cancer Biol Ther. 2020 09 01; 21(9):841-852.
Score: 0.161
-
ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth. Mol Cancer Ther. 2017 Dec; 16(12):2724-2734.
Score: 0.132
-
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Aug 15; 23(16):4642-4650.
Score: 0.128
-
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7(15):20080-92.
Score: 0.119
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
Score: 0.115
-
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014 Jan; 13(1):154-64.
Score: 0.100
-
Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. Rheumatol Int. 2013 Oct; 33(10):2677-81.
Score: 0.092
-
Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012; 7(7):e41834.
Score: 0.092
-
Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. Am J Pathol. 2012 Apr; 180(4):1740-50.
Score: 0.089
-
Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan; 56(1):137-45.
Score: 0.086
-
Targeting NF?B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011 Apr 01; 11(7):678-89.
Score: 0.084
-
Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis. 2010 Oct; 31(10):1787-93.
Score: 0.080
-
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec; 29(6):1132-42.
Score: 0.079
-
Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
Score: 0.029